These findings give rise to the speculation that treatment with EGFR-TKIs in combination with PD-1/PD-L1 inhibition might be beneficial for patients with EGFR-TKI acquired-resistance of NSCLC (Figure 2). Here, EGFR is linked to non-small cell lung carcinoma.